1-(3,5-dimethyl-benzyl)-1H-pyrimidine-2,4-dione | 28484-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dimethyl-benzyl)-1H-pyrimidine-2,4-dione
• 英文别名: 1-[(3,5-Dimethylphenyl)methyl]pyrimidine-2,4-dione
• CAS: 28484-98-2
• 化学式: C₁₃H₁₄N₂O₂
• mdl: MFCD19529604
• 分子量: 230.266
• InChiKey: NPIASNGFWANNPD-UHFFFAOYSA-N

物化性质

• 密度：
  1.207±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯乙酰苯胺 、 1-(3,5-dimethyl-benzyl)-1H-pyrimidine-2,4-dione 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以84%的产率得到2-{3-[(3,5-dimethylphenyl)methyl]-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl}-N-phenylacetamide
  参考文献：
  名称：

  A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides

  摘要：

  A series of heterocyclic compounds were designed as potential nonnucleoside HIV reverse transcriptase inhibitors. Although the compounds ultimately proved inactive against HIV, during the course of the synthesis, a new and highly facile method to realize N-phenylacetamides was developed. Notably, the new route avoids the intractable workups and byproducts previously reported procedures have been associated with, thereby making this approach highly attractive to adaptation with other heterocyclics. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.11.090

文献信息

• <scp>DABCO</scp> mediated one pot synthesis of 2‐(3‐benzyl‐2, 6‐dioxo‐3, 6‐dihydropyrimidin‐1[ <scp>2</scp> <i>H</i> ]‐yl)‐ <i>N</i> ‐(4‐(1, <scp>3‐dioxo‐1</scp> <i>H</i> ‐benzo [ <i>de</i> ]isoquinolin‐2[ <scp>3</scp> <i>H</i> ]‐yl) aryl) acetamides as antimicrobial agents
  作者：Rambabu Sirgamalla、Kurumanna Adem、Sakram Boda、Ashok Kommakula、Suryam Neradi、Shyam Perka、Kiran Bojja、Mohammed Arifuddin

  DOI：10.1002/jhet.4055

  日期：——

  We report herein DABCO mediated one pot synthesis of 2‐(3‐benzyl‐2, 6‐dioxo‐3,6‐dihydropyrimidin‐1[2H]‐yl)‐N‐(4‐(1,3‐dioxo‐1H‐benzo[de]isoquinolin‐2[3H]‐yl) aryl) acetamides (4a‐j). The silent features of this new one pot synthesis include the shorter reaction time, high yields, simple workup, and simultaneous formation of N‐Amide and N‐benzyl bonds in the one pot. The newly synthesized compounds (4a‐j)

  我们在此报告DABCO介导的一锅合成2-（3-苄基-2-，2,6-二氧代-3-，6-二氢嘧啶-1 [2H] -基）-N-（4-（1，3-二氧代-1H-苯并[[]]异喹啉-2 [3H]-基）芳基）乙酰胺（4a-j）。这种新的一锅合成方法的沉默特性包括反应时间更短，产率高，后处理简单以及在一个锅中同时形成N-氨基和N-苄基键。新合成的化合物（4a-j）通过不同的光谱技术进行表征，例如IR，1 H-NMR，13C-NMR，HRMS。对所有合成的化合物的抗菌和抗真菌活性进行了评估。抗菌活性结果表明，化合物4a，4g，4i和4j对金黄色葡萄球菌最具活性。在枯草芽孢杆菌的情况下，发现化合物4a，4i和4j最具活性。化合物4c，4e，4i和4j对大肠杆菌的活性最高。对于铜绿假单胞菌 4a，4i和4j被发现更活跃。另一方面，抗真菌活性结果表明化合物4d，4f，4i和4j对黑曲霉具有更高的活性。发现化合物4
• [EN] ANTI-RETROVIRAL 5,6-DISUBSTITUTED ACYCLOPYRIMIDINE NUCLEOSIDE DERIVATIVES<br/>[FR] DERIVES DE 5,6-BISUBSTITUE ACYCLOPYRIMIDINE NUCLEOSIDE A ACTIVITE ANTIRETROVIRALE
  申请人：UNIV SYDDANSK

  公开号：WO2003057677A1

  公开（公告）日：2003-07-17

  The present invention provides novel pyrimidine nucleoside derivatives represented by the following formula (I): HN I R2 CH (CH2)n 2,X 1∩ D3 wherein R1 represents e.g. an alkyl group; RZ represents e.g. a phenyl group or a 3,5-dimethylphenyl group; and R3 represents e.g. a vinyl group or a ethynyl group; A, B and X represent e.g. oxygene atoms; Z represents e.g. a methylene group or a carbonyl group; n is e.g. 1. The compounds were found to be highly active against wild-type and mutant HIV-1.
• A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides
  作者：Mikhail S. Novikov、Denis A. Babkov、Maria P. Paramonova、Alexander O. Chizhov、Anastasia L. Khandazhinskaya、Katherine L. Seley-Radtke

  DOI：10.1016/j.tetlet.2012.11.090

  日期：2013.2

  A series of heterocyclic compounds were designed as potential nonnucleoside HIV reverse transcriptase inhibitors. Although the compounds ultimately proved inactive against HIV, during the course of the synthesis, a new and highly facile method to realize N-phenylacetamides was developed. Notably, the new route avoids the intractable workups and byproducts previously reported procedures have been associated with, thereby making this approach highly attractive to adaptation with other heterocyclics. (c) 2012 Elsevier Ltd. All rights reserved.